An Open, Randomized, Phase IIIa Study to Evaluate the Safety and Immunogenicity of GSK Biologicals' 10-Valent Pneumococcal Conjugate Vaccine, When Administered Intramuscularly According to a 2-4-11 Months Vaccination Schedule.

Trial Profile

An Open, Randomized, Phase IIIa Study to Evaluate the Safety and Immunogenicity of GSK Biologicals' 10-Valent Pneumococcal Conjugate Vaccine, When Administered Intramuscularly According to a 2-4-11 Months Vaccination Schedule.

Completed
Phase of Trial: Phase III

Latest Information Update: 06 Apr 2017

At a glance

  • Drugs Pneumococcal 10-valent vaccine conjugate (Primary) ; Hib-DTaP-hepatitis B-poliovirus vaccine; Hib-DTaP-poliovirus vaccine
  • Indications Diphtheria; Haemophilus infections; Hepatitis B; Pneumococcal infections; Poliomyelitis; Tetanus
  • Focus Pharmacodynamics; Registrational
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 01 Jul 2011 Planned end date changed from Oct 2011 to Jul 2011 as reported by ClinicalTrials.gov.
    • 09 Jul 2008 Actual patient number (351) added as reported by ClinicalTrials.gov.
    • 09 Jul 2008 Actual end date (Jan 2007) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top